Virus engineered to kill cancer cells tested in first human study

NCT ID NCT06171178

First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 26 times

Summary

This early-phase study tested a lab-modified virus called ASP1012 designed to infect and kill cancer cells while leaving healthy cells alone. It also helps the immune system recognize and attack the cancer. The study included 15 adults with advanced solid tumors who had exhausted standard treatments. Some participants also received the immunotherapy drug pembrolizumab. The trial aimed to find a safe dose and check for side effects, but it was terminated early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Emory Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Gabrail Cancer and Research Center

    Canton, Ohio, 44718, United States

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California, 92663, United States

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Mary Crowley Cancer Research

    Dallas, Texas, 75230, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • The Angeles Clinic and Research Institute

    Los Angeles, California, 90025, United States

  • University of Iowa Hospitals

    Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.